Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference

  //health-fitness.news-articles.net/content/2012/ .. 0th-annual-j-p-morgan-healthcare-conference.html
  Published in Health and Fitness on Wednesday, January 4th 2012 at 13:25 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference -- SAN DIEGO, Jan. 4, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about HALO

[ ]

[ Download image ]

SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: [ HALO ]) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2012 at 2:00 p.m. PT / 5:00 p.m. ET.Greg I. Frost, Ph.D., president and chief executive officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: [ http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ])

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at [ www.halozyme.com ], and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The Company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme's ENHANZE™ Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information, visit [ www.halozyme.com ].

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
[ aerickson@halozyme.com ]

SOURCE Halozyme

RELATED LINKS
[ http://www.halozyme.com ]